From High-Potent APIs to Bioconjugation: Enabling the Next Generation of ADC Therapies

• Outlining TAPI’s capabilities in HPAPIs and bioconjugation
• Exploring innovation in containment, compliance, and sustainability
• Assessing strategic ADC collaborations and future outlook

Speakers:

Tomislav Biljan

Principal Scientist

TAPI